Catalent (NYSE:CTLT) posted its quarterly earnings results on Tuesday. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.08, MarketWatch Earnings reports. Catalent had a return on equity of 14.20% and a net margin of 9.25%. The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $994.28 million. During the same quarter in the prior year, the business earned $0.50 EPS. The firm’s revenue for the quarter was up 38.5% on a year-over-year basis. Catalent updated its FY 2021 guidance to 2.780-2.970 EPS.
Shares of NYSE CTLT opened at $103.50 on Wednesday. The stock has a market capitalization of $17.62 billion, a PE ratio of 65.92, a P/E/G ratio of 2.68 and a beta of 1.50. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.56 and a quick ratio of 2.14. The business has a fifty day moving average price of $108.50 and a two-hundred day moving average price of $106.45. Catalent has a fifty-two week low of $65.00 and a fifty-two week high of $127.68.
Several equities analysts have recently weighed in on the stock. Royal Bank of Canada increased their price objective on shares of Catalent from $125.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, February 3rd. UBS Group raised their price objective on shares of Catalent from $115.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, February 3rd. Morgan Stanley upped their target price on Catalent from $115.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, February 3rd. Argus increased their target price on Catalent from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, March 2nd. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. boosted their price target on Catalent from $110.00 to $130.00 and gave the company an “overweight” rating in a research note on Friday, January 8th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Catalent has a consensus rating of “Buy” and an average price target of $125.11.
Catalent Company Profile
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Featured Story: How are the companies in the S&P 500 selected?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.